Document:

Project Agreement, between the Liverpool School of Tropical Medicine

 Exhibit 10.41 
 

        

 
 Project Agreement 
 Liverpool School of Tropical Medicine (1) 
 and 
 CombinatoRx, Incorporated (2) 
 and

 CombinatoRx (Singapore) PTE. Ltd (3) 
 Distribution Version 2.0 
 Liverpool School of Tropical Medicine, 
 Business/A-WOL Office, 
 Pembroke
Place, 
 Liverpool L3 5QA 
 United Kingdom 

 PROJECT AGREEMENT 
 Relating to ‘Anti-Symbiotic Treatment of Filariasis Consortium 
 (Anti-Wolbachia (A-WOL))’ For Assay Development and Combination High Throughput 
 Screening
(cHTS) (“this Project Agreement”) 
 THIS PROJECT AGREEMENT is made on
8th October 2008 
 BETWEEN:

  

	(1) 	Liverpool School of Tropical Medicine of Pembroke Place, Liverpool, L3 5QA, United Kingdom; (“LSTM”); 

  

	 (2) 
	 CombinatoRx, Incorporated, 245 First St. 16th Floor, Cambridge, MA 02142, U.S.A, on behalf of itself and its subsidiary, CombinatoRx (Singapore) Pte. Ltd. (“Collaborator”); and 

  

	(3) 	CombinatoRx (Singapore) PTE. Ltd a company registered in Singapore and being a subsidiary company of CombinatoRx Incorporated, whose principal place of business is 11
Biopolis Way, Helios #08-05, Singapore 138667. 

 BACKGROUND: 
  

	(A) 	LSTM and The Foundation (as defined in clause 1.1) have entered into the Award Agreement pursuant to which The Foundation has agreed to award the Grant to LSTM and LSTM has agreed
to manage the organisation, development and delivery of the A-WOL Project using a consortium agreement. 

  

	(B) 	LSTM has substantial knowledge on the target organism (Wolbachia) and host. In particular the culture and propagation of Wolbachia using a cell based in-vitro
assay system which will be used to screen the drugs. 

  

	(C) 	Collaborator is a company with in-house expertise in assay development and cHTS. 

  

	(D) 	LSTM and Collaborator have entered into the A-WOL Consortium Agreement, an Interim Consortium Agreement dated 25 April 2007 (“Interim Consortium Agreement”)
and the IP Agreement for the A-WOL Project. 

  

	(E) 	The Parties intend to co-operate in the field of assay development and cHTS of novel drug combinations screened against developed HTS assay systems, in the framework of A-WOL
Consortium Agreement for the purpose of developing an assay system using a combination of drugs to eliminate the target Wolbachia bacteria organism. 

  

	(F) 	The Parties acknowledge that The Foundation is providing funding under the Grant in respect of the A-WOL Project on the condition that the activities associated with the A-WOL
Project (including the managing of technologies and related patents arising out of the A-WOL Project) are conducted in a manner that is consistent with the Award Agreement, the Global Access Strategy, the Global Access Plan as well as the Charitable
Objectives and in furtherance of the A-WOL Project’s scientific objectives contained within the A-WOL Consortium Agreement. 

  

 Page 2 

	(G) 	The Parties have agreed to co-operate with each other in relation to the organisation, development and delivery of the Collaborator Project in accordance with the terms and
conditions of this Project Agreement. 

 THE PARTIES AGREE AS FOLLOWS: 
  

	1.	Definitions and Interpretation 

  

	1.1 	In this Project Agreement, unless the context otherwise requires the following words shall have the following meanings:- 

 “Award Agreement” means the agreement entered into between LSTM and The Foundation
on April 3rd, 2007 in respect of the A-WOL Project, as amended; 
 “A -WOL” means consortium known as Anti-Wolbachia created by the LSTM with (1) The Institute for Medical Microbiology, Immunology and Parasitology, University Clinic Bonn, Bonn,
Germany/Ghana, (2) The Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Harrow, UK/Gambia. (3) TRS LABS Inc., Athens, GA, USA, (4) Collaborator and (5) New England BioLabs, Ipswich, MA, USA;

 “A-WOL Consortium Agreement” means the consortium agreement of that name signed by LSTM and the other A—WOL
consortium members effective on 1 January 2008 and signed by Collaborator by way of an accession agreement effective on 1 April 2008 (“Accession Agreement”); 
 “A-WOL Management Committee” shall have the meaning set out in the A-WOL Consortium Agreement; 
 “A-WOL Project” means the project entitled ‘Anti-Symbiotic Treatment of Filariasis’ as referred to in the Award Agreement,
which will comprise a number of sub-projects including the Collaborator Project; 
 “Background IPR” shall have the meaning
provided in the A-WOL Consortium Agreement, as modified by the IP Agreement; 
 “Charitable Objectives” mean the charitable
goals, principles and objectives of the A-WOL Project which are (i) the prompt and broad dissemination of new scientific information to the scientific community (subject to a limited delay to seek IPR protection if such protection would best
facilitate the achievement of the A-WOL Project’s charitable goals) and (ii) to ensure that innovations and related rights are managed in a manner that furthers the objectives of enabling the subsequent accessibility of the developed
products and health solutions (with respect to cost, quantity and applicability) by the people most in need within the Disease Endemic Countries; 
  

 Page 3 

 “Collaborator Project” means the sub-project described in the Complete Project
Specification and to be undertaken by the Collaborator under this Project Agreement including without limitation the Collaborator Project Research; 
 “Collaborator Project Research” means the research involved in the Collaborator Project and as referred to in the Complete Project Specification and any research or activities by the Parties funded whether directly or
indirectly, in whole or in part by the Grant; 
 “Commencement Date” means 1 April 2008; 
 “Complete Project Specification” means the specification, work plan and budget in respect of the Project detailed in Schedule 1;

 “Confidential Information” means any information or materials of a scientific, clinical, experimental, technical or
financial nature which relates to the business, research, products, technology, IPR, operations, customers, business partners or finances of a Party or The Foundation and any other information which if disclosed to a third party could adversely
affect the other Party or The Foundation and which in each case is either clearly identified as being confidential and/or proprietary at the time of disclosure or which by virtue of its content and nature reasonably ought to be assumed as being
confidential and/or proprietary; 
 “Disease Endemic Countries” shall have the meaning ascribed to it in the A-WOL Consortium
Agreement; 
 “Filariasis” means the parasitic disease caused by any of the thread-like filarial worms including without
limitation Wulchereria bancrofti, Brugia malayi, Brugia timori and O. volvulus; 
 “Foreground IPR”
shall have the meaning provided in the A-WOL Consortium Agreement, as modified by the IP Agreement; 
 “Global Access
Plan” means the global access plan in respect of the A-WOL Project detailed in A-WOL Consortium Agreement; 
 “Global Access
Strategy” means the global access strategy in respect of the A-WOL Project detailed in the A-WOL Consortium Agreement; 
 “Grant” means the project support financial grant awarded by the LSTM to the Parties in support of the A-WOL Project; 
 “IP Agreement” means the Co-Ownership Agreement Relating to Intellectual Property Rights, of even date entered into by LSTM and the Collaborator and being effective on 1 April 2008; 
 “IPR” shall have the meaning provided in the A-WOL Consortium Agreement, as modified by the IP Agreement; 
 “Onchocerciasis” means the parasitic disease caused by the parasitic filarial worm O. volvulus; 
  

 Page 4 

 “Parties” shall collectively mean each of the parties to this Project Agreement as
applicable and “Party” shall mean any one of them as applicable; 
 “Product” shall have the meaning set
forth in the A-WOL Consortium Agreement; 
 “Project Agreement” means this agreement and all its schedules as amended from
time to time. Schedule 1 (Complete Project Specification), Schedule 2 (Provisions Relating to the Award Agreement), Schedule 3 (Contact Details) and Schedule 4 (Reporting Accounting and Payment Schedule) are hereby incorporated into this Project
Agreement by this reference. Unless expressly specified within a Schedule all capitalised terms in the schedules shall have the same definition as provided in this Project Agreement; 
 “The Foundation” means the Bill & Melinda Gates Foundation; 
 “Wolbachia” means the bacteria of the genus Wolbachia which are intracellular bacteria and endosymbionts of
filarial nematodes. 
  

	1.2 	Headings in this Project Agreement are for ease of reference only and do not affect the interpretation of this Project Agreement. References to clauses and Schedules are references
to clauses in and Schedules to this Project Agreement, references to the singular includes the plural and vice versa and references to ‘including’ and similar expressions shall be interpreted without limitation.

  

	1.3 	The Schedules and the documents annexed to the Schedules shall form part of this Project Agreement to the extent described herein and in the event of any conflict between the
provisions of this Project Agreement and the Schedules and/or those documents the provisions of this Project Agreement shall prevail (except in the case of the Global Access Strategy and Global Access Plan contained within the A-WOL Consortium
Agreement). 

  

	2.	Structure of the Project 

  

	2.1 	The aims and objectives of the Collaborator Project, and the work to be carried out by each Party, are described in detail in the Complete Project Specification in Schedule 1 and
the Global Access Plan contained within the A-WOL Consortium Agreement. 

  

	2.2 	The operation of the A-WOL Management Committee of the A-WOL Project is outlined in the A-WOL Consortium Agreement. Collaborator shall be represented on the A-WOL Management
Committee by one duly appointed employee, for the purpose of managing the performance and progress of the Collaborator Project, reviewing the inventions arising thereof, and reporting to LSTM in respect of the Collaborator Project. Collaborator
understands that its representative is to be guided by the goals of achieving both the A-WOL Project’s (as defined in the A-WOL Consortium Agreement) scientific objectives as well as the Charitable Objectives. Management of the Collaborator
Project with Collaborator shall be in accordance with this Project Agreement and having particular regard to the Charitable Objectives. Collaborator shall be responsible for: 

  

	 	a.	appointing a Collaborator Project co-ordinator who will be the primary contact between LSTM and A-WOL; 

  

 Page 5 

	 	b.	meeting (de visu or via telecommunication means) every quarter if needed and at least once every six (6) months; 

  

	 	c.	approval of all the formal technical and progress reports that are submitted to LSTM in accordance with Schedule 4; 

  

	 	d.	identification and appointment of any new members of the Collaborator Project team; 

  

	 	e.	assisting with the decision making and technical direction of the Collaborator Project, including the updates and revisions that are required for the Complete Project Specification,
and Global Access Plan contained within the A-WOL Consortium Agreement; and 

  

	 	f.	reporting the creation of IPR to the A-WOL Management Committee and discussing the steps to be taken to protect IPR in accordance with the A-WOL Consortium Agreement and the IP
Agreement. 

  

	2.3 	The Collaborator Project and this Project Agreement (including the Complete Project Specification) will be reviewed annually and at such other times as may be reasonably necessary
taking into account all applicable circumstances by the Parties and the A-WOL Management Committee. All changes or updates which may be necessary in respect thereof will be subject to the agreement of the Parties in writing in accordance with clause
12.1 and shall be referred to the A-WOL Management Committee for ratification prior to any such changes or updates coming into effect. 

  

	3.	The Parties’ general performance obligations 

  

	3.1 	The Parties each agree to perform the Collaborator Project in accordance with this Project Agreement, the A-WOL Consortium Agreement, the IP Agreement and all other applicable terms
of reference and documents referred to herein. 

  

	3.2 	The Parties shall take all reasonably necessary measures to perform and fulfil, promptly and in due time, all their obligations in respect of the Collaborator Project (including the
performance of activities and delivery of deliverables under the Complete Project Specification) so that the Collaborator Project is carried out in accordance with clause 3.1. In doing so and without prejudice to the generality of the foregoing,
each Party shall: 

  

	 	3.2.1 	act with reasonable skill, care and diligence and in a professional manner; 

  

	 	3.2.2 	employ, engage and use suitably skilled and appropriately experienced, trained and qualified personnel; 

  

	 	3.2.3 	provide and contribute all time, resources (including human, material and intellectual resources), equipment and facilities which may be reasonably necessary for that purpose;

  

 Page 6 

	 	3.2.4 	use its reasonable efforts to ensure that the results of the Collaborator Project are obtained and the purpose of the Collaborator Project is satisfied; 

  

	 	3.2.5 	notify each other promptly and without unreasonable delay in the performance of the Collaborator Project or of any relevant factors or events that may materially impact or affect
the Collaborator Project and/or the A-WOL Project (as appropriate) or its progress; 

  

	 	3.2.6 	ensure the accuracy of any deliverables, information, reports or materials it supplies pursuant to this Project Agreement; 

  

	 	3.2.7 	act at all times reasonably, in good faith, in accordance with good business ethics and in a manner that reflects and does not harm or damage, whether by way of any act, omission or
statement, the good name, goodwill and reputation of the Parties, the A-WOL Consortium members and/or The Foundation; 

  

	 	3.2.8 	comply with all applicable laws and regulations in connection with all its activities in respect of the Collaborator Project; and 

  

	 	3.2.9 	keep each other reasonably well informed of its activities and progress in respect of the Collaborator Project and all material information related thereto from time to time and
promptly and without unreasonable delay following any request. 

 For the avoidance of doubt, whilst the Parties will use all
reasonable endeavours to perform the Collaborator Project according to the Complete Project Specification they do not guarantee that the work carried out will lead to any particular result nor is the success of such work guaranteed. 
  

	3.3 	Each Party warrants and represents that it has all necessary rights, powers and authority to enter into this Project Agreement, perform its obligations hereunder and grant all
rights which are granted by it under and pursuant to this Project Agreement. 

  

	4.	Provisions relating to the Award Agreement 

  

	 	4.1 	LSTM is required by the Award Agreement to impose a number of obligations and restrictions relating to best practice upon all participants involved in the A-WOL Project, which are
reflected in the provisions of this Project Agreement and/or are set out in Schedule 2, and the Parties agree to use all reasonable endeavours to comply with all such obligations and restrictions. 

  

	5.	Financial Provisions, Indemnification and Liability 

  

	 	5.1 	LSTM will make payments to Collaborator according to the actual costs which the Collaborator incurs in respect of the Collaborator Project in accordance with the budgets contained
in Schedule 4. If Collaborator is to incur actual costs wholly, properly and reasonably incurred as a result of the Collaborator Project in respect of any period which are in excess of such budgeted costs for that period and Collaborator wishes to
subsequently receive payments in respect of such excess, Collaborator must obtain the prior written approval of LSTM in respect of such excess. 

  

 Page 7 

	5.2	LSTM will make such Grant payments calendar quarterly in advance subject to: 

  

	 	 5.2.1 
	 having received the accounts and reconciliation referred to in clause 6.2 in respect of the calendar quarter preceding
the previous calendar quarter (so that, for example, LSTM will not make a Grant payment on 1st July in respect of the calendar quarter running
from 1st July to 30th September until
it has received the accounts and reconciliation referred to in clause 6.2 in respect of the calendar quarter running from 1st January to 31
st March); and 

  

	 	5.2.2 	adjusting such payments to allow for reconciliation of actual and budgeted costs. 

  

	5.3 	The payments made to Collaborator and interest earnings thereon can be used by the Collaborator and approved sub-contractors appointed under clause 12.3 solely for the purposes of
the Collaborator Project. 

  

	5.4 	Grant payments by LSTM shall be made in US Dollars (US$). 

  

	5.5 	Grant payments by LSTM shall be made by direct credit transfer to the Collaborator’s bank account, details of which it shall provide to LSTM in advance. The Collaborator shall
provide to LSTM appropriate invoices in respect of each such Grant payment in accordance with LSTM’s reasonable instructions. 

  

	5.6 	LSTM may deduct and withhold from Grant payments the costs associated with such transfers in clause 5.5 above and any other sums which LSTM is required by applicable law to deduct
or withhold and the Collaborator shall bear the entire risk associated with any fluctuations in foreign exchange rates. 

  

	5.7 	LSTM shall have no liability to transfer any Grant payments until they are received by it from The Foundation. 

  

	5.8 	Except for any Grant payments which may be due to it pursuant to this Project Agreement, each Party shall bear all of its own costs, expenses, risks and liabilities in connection
with this Project Agreement including the preparation and negotiation of this Project Agreement. 

  

	5.9 	The Collaborator agrees that LSTM shall have no liability for or in respect of any refunds of Grant payments by the Parties which may be required in accordance with this Project
Agreement or by The Foundation in accordance with the Award Agreement. LSTM shall notify in writing the Collaborator promptly upon its knowledge of any such requirements for refunds. 

  

	5.10 	 Subject to Clause 18 of the IP Agreement (Indemnity), Collaborator agrees to defend and hold LSTM harmless, to the fullest extent permitted by applicable law, from
and against any and all liability, loss, damages, costs or expenses (including reasonable legal fees and disbursements) (“Losses”) incurred by LSTM as a result of any claims (including claims for injury or damages) or demands
brought or made against LSTM by 

  

 Page 8 

	 	 
The Foundation (including pursuant to any indemnification provisions contained in the Award Agreement) or any third parties arising out of or resulting from
any acts or omissions of the Collaborator or of any of its officers’, agents’, employees’, contractors’ or sub-contractors’ breach of its obligations hereunder, gross negligence or willful misconduct; provided, however, that
Collaborator shall have no obligation to indemnify, defend or hold LSTM harmless for any Losses that are the result of the negligence or wilful misconduct of LSTM or of another party to the A-WOL Consortium Agreement. 

 

	5.11 	In no event shall LSTM have any liability to Collaborator at any time in excess of the amount of Collaborator’s allocation of the Grant which is due and payable to Collaborator
from LSTM in accordance with this Project Agreement on or before that time. 

  

	5.12 	Each Party must maintain at its own expense throughout the duration of this Project Agreement either appropriate insurance policies as required by its institution or governing body
(if applicable) or appropriate self insurance if permitted by its institution or governing body (if applicable) which, in each case, must cover such Party’s potential liabilities under this Project Agreement and professional, public and
employer’s liability risks. Each Party must give any other Party evidence of those insurance policies or such self insurance if such other Party seeks such evidence in writing. 

  

	6.	Reporting, Assistance and Records 

  

	6.1 	Each Party will provide the deliverables, accounts and information set out in the Complete Project Specification (Schedule 1) and the Reporting, Accounting and Payment Schedule
(Schedule 4). 

  

	6.2 	Each Party agrees to maintain detailed and accurate accounting records both during and for at least six (6) years after the term of this Project Agreement (or, if longer, for
at least seven (7) years from the end of the financial year in which any such accounting records were created) to enable expenditure of the Grant funds received by it to be verified. Such accounting records of any Party must be sufficient to
explain its material financial transactions relating to the Collaborator Project so that the financial position of that Party at any time in connection with the Collaborator Project can easily be ascertained. 

  

	6.3 	Collaborator will throughout the periods of time referred to in clause 6.2 make its accounting records available for inspection – subject to appropriate confidentiality
undertaking not less strict than those contained herein—by LSTM, The Foundation and/or their designated representatives or accountants upon reasonable written notice during mutually agreeable business hours and permit LSTM and/or The Foundation
to monitor and conduct an evaluation of operations relating to the Collaborator Project. Such inspection may include a visit by LSTM and/or The Foundation’s personnel or designee to observe its activities, program, trial protocols, a discussion
of the program with Collaborator’s staff, and a review of financial and other records connected with the Grant, subject to reasonable prior written notice and not exceeding five (5) days a year. 

  

 Page 9 

	7.	IPR 

  

	7.1 	All matters regarding IPR are detailed in the A-WOL Consortium Agreement and the IP Agreement. 

  

	8.	Publication, Grant Announcements and Publicity 

  

	8.1 	The Parties shall comply with the obligations and restrictions regarding publications related to the Collaborator Project as part of the A-WOL Project as set out in the A-WOL
Consortium Agreement. 

  

	8.2 	If Collaborator wishes to publicise by any means its participation in the A-WOL Project and/or the Collaborator Project it must follow the process for scrutiny of publications set
out in the A-WOL Consortium Agreement. 

  

	8.3 	Under no circumstances may Collaborator make any implication to investors, media or the general public that The Foundation supports its activities, except as required by applicable
law. 

  

	8.4 	The Parties acknowledge that The Foundation and LSTM may make information about the Grant public at any time, subject to the confidentiality provisions of the A-WOL Consortium
Agreement. 

  

	9.	Term and Termination 

  

	9.1 	This Project Agreement shall come into effect on the Commencement Date and this Project Agreement shall continue thereafter until it is terminated in accordance with this clause 9.
The consequences of any termination are addressed in the A-WOL Consortium Agreement. 

  

	9.2 	This Project Agreement will automatically terminate upon the expiry or termination of: 

  

	 	9.2.1 	the Award Agreement; 

  

	 	9.2.2 	the whole of the A-WOL Consortium Agreement; 

  

	 	9.2.3 	Collaborator’s involvement under the A-WOL Consortium Agreement; and/or 

  

	 	9.2.4 	the withdrawal of the Grant by The Foundation. 

  

	9.3 	This Project Agreement can be terminated at any time subject to mutual agreement of the Parties in writing. 

  

	9.4 	This Project Agreement may be terminated with immediate effect by a Party (“Terminating Party”) upon the giving of a written notice of termination to that the other
Party: 

  

	 	9.4.1 	if the other Party is in persistent and/or material breach of this Project Agreement and fails to remedy the same within thirty (30) days of being notified in writing to do so
by the Terminating Party; or 

  

 Page 10 

	 	9.4.2 	if an order is made or a resolution passed for the winding up of the other Party (other than voluntarily for the purpose of solvent amalgamation or reconstruction), or if the other
Party goes into liquidation, or if an administrator, administrative receiver or receiver is appointed in respect of the whole or any part of the other Party’s assets, or if the other Party makes an assignment for the benefit of or composition
with its creditors generally, or threatens to do any of these things, or if anything in any other jurisdiction happens in respect of the other Party which is similar to any of the foregoing, or if that other Party ceases to carry on business.

  

	9.5 	A Party may terminate its participation in this Project Agreement on expiration of not less than six (6) months’ prior written notice of such termination and the reasons
for it (such as commercial or regulatory considerations, or disagreement with any substantial terms of a future phase of the Collaborator Project according to clause 2.3) to the other Party. 

  

	9.6 	Any expiry or termination of this Project Agreement shall not affect any accrued rights or liabilities of a Party nor the coming or continuance in force of any provisions of, and
the Parties’ obligations under clauses 5, 6, 7, 8, 9, 10, 11 and 12 of this Project Agreement which are expressly or by reasonable implication intended to come into or continue in force on or after such expiry or termination; except that in the
case of termination for breach, the breaching Party hereunder shall not retain its accrued rights but shall remain bound by its accrued obligations. 

  

	9.7 	Upon any expiry or termination of this Project Agreement, Collaborator shall promptly refund to LSTM any Grant funds previously received by it which have not been spent or committed
by it in accordance with this Project Agreement. 

  

	10.	Confidentiality 

  

	10.1 	For the term of this Project Agreement and ten (10) years thereafter, each Party shall not disclose or permit the disclosure of any Confidential Information of the other Party,
nor shall a Party use any Confidential Information of the other Party for any purpose other than this Project Agreement and/or the A-WOL Consortium Agreement. 

  

	10.2 	Each Party shall ensure that any of its staff, employees and/or officers who have access to the Confidential Information are bound by a duty of confidentiality and properly informed
of their obligations under this Project Agreement. 

  

	10.3 	This clause 10 shall not apply in respect of any information which the receiving Party can prove: 

  

	 	10.3.1	 to have been known (without being subject to any confidentiality obligations) to the receiving Party at the time of receipt, as evidenced by dated written records;

  

	 	10.3.2	 was in the public domain or generally known to the public at the time of its disclosure to the receiving Party or which subsequently becomes part of the public domain in any
manner other than by violation of the terms of this Project Agreement; 

  

 Page 11 

	 	10.3.3	 is received from other sources without any breach of any obligations regarding the preservation of the confidentiality thereof; 

  

	 	10.3.4	 is confirmed in writing by the disclosing Party prior to disclosure by the other Party to not be subject to this clause 10; 

  

	 	10.3.5	 by documentary evidence, to have been independently developed by the receiving Party outside of this Project Agreement; or 

  

	 	10.3.6	 the receiving Party is required to disclose by law or by governmental, regulatory or judicial body or authority of competent jurisdiction provided that the receiving Party
shall give the disclosing Party as much prior notice thereof as reasonably practical prior to disclosure and the receiving Party shall use reasonable efforts to limit the disclosure as far as it is legally entitled to and shall provide such
assistance as the disclosing Party may reasonably request for such purpose; or 

  

	 	10.3.7	 is agreed to be published as provided hereunder. 

  

	10.4 	Each Party shall return to the other Party that other Party’s Confidential Information and any copies, summaries and/or extracts thereof promptly following receipt of a request
to do so from that other Party in writing and in any case upon the expiry or termination of this Project Agreement and shall not retain any copies thereof other than solely for the purpose of performing its obligations under this Project Agreement
and exercising the rights and licenses granted to it under this Project Agreement. 

  

	10.5 	The Parties agree that money damages will not be a sufficient remedy for any breach of this clause 10 by the other and Collaborator or LSTM, as the case may be, shall be entitled,
in addition to money damages, to specific performance and injunctive relief and any other appropriate equitable remedies for any such breach. Such remedies shall not be deemed to be the exclusive remedies for a breach of this clause 10 but shall be
in addition to all other remedies available at law or in equity. 

  

	11.	Dispute Resolution 

  

	11.1 	All matters regarding dispute resolution are detailed in the A-WOL Consortium Agreement, as modified by the Accession Agreement entered into between the Parties on even date.

  

	12.	General 

  

	12.1 	 Communications between the Parties shall be addressed to each other for the attention of the personnel or departments (as applicable) indicated in Schedule 3. Any
formal notice given by any Party to any of the others pursuant to this Project Agreement (including notices referred to in clause 9) shall be in writing addressed to any such other Party at its address set out above or such other address as may
either be set out in Schedule 3 or as may have been notified pursuant to this clause to the Party giving the notice. Any notice, consent, approval, agreement or other document required under this Project Agreement shall, in the absence of any
express provision to the contrary shall be in writing in the English language and shall be deemed to have been duly given if left at or sent by hand or by registered post (or airmail as appropriate) or by fax to a 

  

 Page 12 

	 	 
Party at the address set out at the beginning of this Project Agreement for such Party or such other address as one Party may from time to time designate by
written notice to the other and will be deemed to have been received by the other Party; (i) two (2) Working Days following the date of dispatch if the notice or other document is sent by registered post, or (ii) seven
(7) Working Days following the date of dispatch if the notice or other document is sent by registered airmail post, or (iii) simultaneously with the delivery if sent by hand, or (iv) simultaneously with transmission if sent by fax
provided that the sending transmitting party keeps a copy of a transmission report illustrating successful transmission to the appropriate fax number. 

  

	12.2 	This Project Agreement supersedes any prior written or oral agreements, arrangements and undertakings between the Parties relating to the subject matter of this Project Agreement
and shall, together with the Schedules hereto and the AWOL Consortium Agreement with the Schedules thereto, the Accession Agreement, the Interim Consortium Agreement and the IP Agreement constitute the entire agreement and understanding between both
the Parties relating to its subject matter. No addition to or modification of this Project Agreement (including the Schedules) shall be binding upon the Parties unless made by an authorised representative of the Parties in writing. The Parties shall
act reasonably in implementing any additions or modifications which may be required by The Foundation. Each Party confirms it has not entered into this Project Agreement on the basis of any representations that are not expressly incorporated in this
Project Agreement provided that nothing in this Project Agreement purports to exclude liability for any fraudulent statement or act. 

  

	12.3 	Subject to Clause 12.4, no rights or obligations of a Party arising under this Project Agreement may be assigned, transferred, sub-licensed, sub-contracted or otherwise delegated in
whole or in part to any third party without the prior written approval of the other Party. In the event that a Party assigns, transfers, sub-licenses, sub-contracts or otherwise delegates to a third party as aforesaid it shall remain fully
responsible and liable for the acts and omissions of any such third party in respect of the Project. 

  

	12.4 	In the event that the LSTM should re-organise the management of its portfolio so as to create a new legal entity for the management of the A-WOL Project, LSTM may transfer this
Project Agreement and all its associated rights and responsibilities to such a new entity. 

  

	12.5 	Nothing in this Project Agreement shall constitute or imply a partnership, joint venture, agency, employment or other relationship between the Parties other than the contractual
relationship expressly provided for in this Project Agreement, and the A-WOL Consortium Agreement, the Accession Agreement, the Interim Consortium Agreement and the IP Agreement and neither Party shall hold itself out or act in such a way as may
give that impression (including by using the other Party’s name) or do anything to bind or create any obligation or responsibility upon the other Party without the other Party’s prior written approval. 

  

	12.6 	No delay or failure by a Party to exercise or enforce any right, power or remedy under this Project Agreement shall constitute or operate as a waiver of that right, power or remedy
or any other right, power or remedy under this Project Agreement or operate so as to prevent the subsequent exercise or enforcement of any such right, power or remedy. Any waiver must be made by the waiving Party in writing to be effective.

  

 Page 13 

	12.7 	If any term of this Project Agreement shall become or be declared illegal, invalid or unenforceable for any reason whatsoever it shall not affect the other provisions of this
Project Agreement provided always that if any such deletion substantially affects or alters the basis of this Project Agreement the Parties shall amend the terms of this Project Agreement as may be necessary in the circumstances.

  

	12.8 	Any claim or legal proceedings brought against a Party in relation to this Project Agreement shall be governed by the law of England and Wales and subject to clause 11 hereto, the
Parties hereby submit to the exclusive jurisdiction of the Courts of England. 

  

	12.9 	This Project Agreement may be executed in one (1) or more counterparts by the Parties, each of which, when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same instrument, provided that this Project Agreement shall be of no force and effect until the counterparts are exchanged. Signatures may be exchanged by facsimile or electronic means with original signatures
to follow by post. Each of the Parties agrees to be bound by its own facsimile or electronic form signature and that is accepts the facsimile or electronic form signature of the other party. 

  

 Page 14 

 IN WITNESS WHEREOF duly authorised representatives of the Parties have signed this Project Agreement 
  

					
	 Signed for and on behalf of
 Liverpool School of
Tropical Medicine
	 		 	
			
	 	 		 	/s/ S. A. Ward
		 		 	 Signature
  
 S. A. Ward
 Name
  
 Deputy Director
 Title
  
 10/3/2008
 Date

	 Signed for and on behalf of
 CombinatoRx,
Incorporated
	 		 	
			
	 	 		 	/s/ Alexis Borisy
		 		 	 Signature
  
 Alexis Borisy
 Name
  
 President and CEO
 Title
  
 10/8/2008
 Date

	 Signed for and on behalf of
 CombinatoRx (Singapore)
PTE. Ltd.
	 		 	
			
	 	 		 	/s/ Ralf Altmeyer
		 		 	 Signature
  
 Ralf Altmeyer
 Name
  
 President, CRx-SG
 Title
  
 10/8/2008
 Date

  

 Page 15 

 Schedule 1 
 Complete Project Specification 
 [Omitted] 
  

 Page 16 

 Schedule 2 
 Provisions relating to the Award Agreement 
  

	(a)	Anti-Terrorism. Each Party confirms that it is familiar with the U.S. Executive Orders and laws that prohibit the provision of resources and support to individuals and
organisations associated with terrorism and the terrorist related lists promulgated by the U.S. Government, the United Nations, and the European Union. Each Party confirms that it will take reasonable precautions to ensure that none of the Grant
funds will be used in support of or to promote violence, terrorist activity or related training, whether directly through its own activities and programs, or indirectly through its support of, or cooperation with, other persons and organisations
known to support terrorism or that are involved in money laundering activities. 

  

	(b)	Compliance by all Parties. Each Party warrants and represents that it has or will obtain all necessary regulatory and governmental licenses required for it to pursue the
Project. 

  

	(c)	Primary Grantee Compliance. Each Party acknowledges that pursuant to the provisions of the Award Agreement, if The Foundation is not satisfied with the progress of the
Project or the content of any written report, The Foundation reserves the right at its discretion to cancel all or part of the Grant, discontinue funding the Project and request that all or part of any unspent and uncommitted Grant funds previously
distributed to LSTM or it by or on behalf of The Foundation are returned to The Foundation. Expiration or termination of all or part of the Grant will not affect any rights or obligations which have accrued prior thereto. 

 

	(d)	Research Practice Assurances - Coverage for all sites. As a term and condition of the Grant, each Party agrees for each venue in which any part of the Project is conducted by
it to comply with, assure and gain timely, appropriate prior approval for all activities subject to regulation and/or other types of required assurances or legal requirements. Such regulated activities include things such as: research involving
human subjects, clinical trials, including management of data confidentiality, research involving animals; research using substances or organisms classified as Select Agents by the U.S. Government; use or release of genetically modified organisms;
use of recombinant DNA; and/or use of any organism, substance or material considered to be a biohazard, including adherence to all applicable standards for transport of specimens, both locally and internationally, as appropriate. As applicable,
regulated activities and their documentation are to be conducted under the relevant international, national, and local standards. Documentation of research practices should be consistent with the need to establish corroborated dates of invention and
reduction to practice with respect to inventions where this is relevant. 

  

	(e)	Research Practice Assurances - Institutional Review Board (IRB) Approval. For research involving human subjects as a condition of the Grant each Party agrees that the
appropriate IRBs and ethical committees will review and approve all final protocols prior to enrollment of the first subject in respect of the Project. No Grant funds may be expended to enroll human subjects until appropriate regulatory and ethical
bodies’ approvals are obtained. A similar provision applies to Institutional Animal Care and Use Committee approval of studies involving animals, and Institutional Biosafety Committee for biohazards and recombinant DNA. Each Party agrees to
provide prompt notice to LSTM and The Foundation if the facts and circumstances change for any of the topics listed. 

  

 Page 17 

	(f)	Research Practice Assurances - Provision of Care for Human Subjects Research. By accepting the Grant, in keeping with “Good Clinical Practice” standards, each Party
agrees to disclose to applicable subjects and the IRBs what care and/or referrals will be available through participation in the Project. Institutional policies regarding what care will be provided to personnel who are injured as a result of their
work on the Project should be similarly developed, approved and implemented with notice to the employees. 

  

	(g)	Research Practice Assurances - Good Clinical Practices. Each Party agrees to conduct clinical trials associated with the Project under the generally accepted principles of
“Good Clinical Practices” as defined by the International Conference on Harmonization (ICH)-E6 and incorporated, for example, by the United States Food and Drug Administration (FDA) or the European Agency for the Evaluation of Medicinal
Products (EMEA). Each Party acknowledges and agrees that it will have full responsibility to LSTM and The Foundation for all compliance, safety, monitoring and audit requirements of the relevant regulatory agencies, for all of its sites included in
the Project 

  

 Page 18 

 Schedule 3 
 Contact Details 
 Address: 
 CombinatoRx Inc 
 245 First Street 
 16th Floor

 Cambridge 
 Massachusetts 02142 
 USA 
 Tel: 617 301 7000 
 Fax: 617 301 7010 
 CombinatoRx Inc 
 11 Biopolis Way 
 Helios #08-0506 
 Singapore 
 SGP 138667 
 DID (Direct Inward Dialling) 
 Tel (DID): + 65 6773 7915 

Tel: +65 6773 7915 
 Fax: +65 6775 9857 
 Formal notices 
 Jason F. Cole, Esq.: 
 Tel: 617 301 7035 
 e-mail: jcole@combinatorx.com

 General Project related communications 
 Indira
Umareddy: Based in Singapore 
 Tel: DID +65 6773 2052 
 Tel: 65 924 87716 
 e-mail: iumareddy@combinatorx.com 
 Ralf Altmeyer: Based in Singapore 
 Tel: DID +65 6773 7905 
 Tel: +65 93380698 
 e-mail: raltmeyer@combinatorx.com

  

 Page 19 

 Communications relating to Financial Matters 
 Joanne Tan: Based in Singapore 
 Tel: +65 6773 7902 
 e-mail: jtan@combinatorx.com 
 Joe Pucek: Based in Cambridge 
 Tel: +617 301 7086 
 e-mail: jpucek@combinatorx.com

  

 Page 20 

 Schedule 4 
 Reporting Accounting and Payment Schedule. 
 The reports are requested on a quarterly basis by the financial officer
at LSTM. The time lines are outlined below: 
  

			
	 Quarterly period
	  	 Report requested

	 April – June
	  	August
	 July – September
	  	November
	 October – December
	  	February
	 January – March
	  	May

 Budget for the Collaborator Project has been allocated. The annual budget for Collaborator (Activity 3) is listed
below – figures are in US dollars (US $) 
  

																			
	 Consortium member
	  	Year 1	  	Year 2	  	Year 3	  	Year 4	  	Year 5	  	Total
allocated
	 CombinatoRx
	  	$	690,000	  	$	862,500	  	$	862,500	  	$	862,500	  	$	690,000	  	$	3,967,500

  

 Page 21Co-Ownership Agreement, between the Liverpool School of Tropical Medicine

 Exhibit 10.42 
 DATED 8 October 2008 
 LIVERPOOL SCHOOL OF TROPICAL MEDICINE (1) 
 and 
 COMBINATORX INCORPORATED (2)

 and 
 COMBINATORX
(SINGAPORE) PTE. LTD (3) 
  
  
 CO-OWNERSHIP AGREEMENT RELATING TO INTELLECTUAL PROPERTY RIGHTS 
 A-WOL CONSORTIUM 
  
  
 WALKER MORRIS 

Kings Court 
 12 King Street 

 LEEDS 
 LS1 2HL 

 Tel: 0113 2832500 
 Fax: 0113 2459412 
 Ref: LIV.200-3 

 CONTENTS 
  

					
	 SECTION
	  	 HEADING
	  	PAGE
	 1
	  	DEFINITIONS AND INTERPRETATION	  	2
			
	 2
	  	INTERESTS OF PARTIES	  	5
			
	 3
	  	FIELD OF USE	  	5
			
	 4
	  	BACKGROUND IPR	  	6
			
	 5
	  	PATENTS	  	7
			
	 6
	  	RENEWAL FEES	  	8
			
	 7
	  	INDEPENDENT WORKING	  	9
			
	 8
	  	LICENCE RESTRICTION	  	9
			
	 9
	  	DIVISION OF PROFITS FROM LICENCE	  	9
			
	 10
	  	SALE OR ASSIGNMENT OF INTEREST & RIGHTS OF PRE-EMPTION	  	9
			
	 11
	  	SURRENDER	  	10
			
	 12
	  	INFRINGEMENT PROCEEDINGS	  	11
			
	 13
	  	MARKING OF PRODUCTS	  	12
			
	 14
	  	AMENDMENT OF SPECIFICATION	  	12
			
	 15
	  	ACKNOWLEDGEMENT	  	12
			
	 16
	  	REGISTRATION	  	12
			
	 17
	  	IP STEERING COMMITTEE	  	13
			
	 18
	  	INDEMNITY	  	13
			
	 19
	  	CONFIDENTIALITY	  	13
			
	 20
	  	TERM AND TERMINATION	  	13
			
	 21
	  	GENERAL	  	13
			
	 SCHEDULE
	  	IP STEERING COMMITTEE	  	16

					
	 THIS AGREEMENT is made on
	  	8th October	  	2008

 BETWEEN: 
  

	(1)	LIVERPOOL SCHOOL OF TROPICAL MEDICINE a company limited by guarantee and incorporated in England and Wales (No: 83405) and being registered charity (No: 222655) whose
registered office is situated at Prembroke Place, Liverpool, L3 5QA, United Kingdom (LSTM); and 

  

	 (2)
	 COMBINATORX INCORPORATED, a corporation incorporated in Delaware, USA whose principal place of business is 245
First Street, 16th Floor, Cambridge, MA 02142, USA; and 

  

	(3)	COMBINATORX (SINGAPORE) PTE. LTD. a company registered in Singapore and being a subsidiary company of CombinatoRx Incorporated, whose principal place of business is 11
Biopolis Way, Helios #08-05, Singapore 138667. 

 CombinatoRx Incorporated and CombinatoRx (Singapore) PTE. Ltd shall be
referred to collectively as “CombinatoRx”. Each of LSTM and CombinatoRx are referred to as a ‘party’ and together ‘the parties’. 
 BACKGROUND 
  

	(A)	LSTM and CombinatoRx are both parties to the Consortium Agreement relating to the Anti-Symbiotic Treatment of Filariasis Consortium (A-WOL) by way of the Accession Agreement
introducing a new member to the A-WOL Consortium effective on 1 April 2008 (Consortium Agreement). 

  

	(B)	The parties have agreed to vary CombinatoRx’s membership to the Consortium Agreement relating to the ownership of the intellectual property rights by way of this Co-ownership
Agreement. 

  

	(C)	It is a requirement under the Consortium Agreement that LSTM owns any Foreground IPR (as defined below). It is also a requirement of CombinatoRx’s corporate structure that it
owns any IPR (as defined below) which it creates on behalf of third parties. 

  

	(D)	The parties have agreed that co-ownership of the Foreground IPR is a commercially viable solution and wish to define their respective rights and liabilities under the Foreground IPR
on the terms and conditions of this Agreement. 

  

 Page 1 

	1	DEFINITIONS AND INTERPRETATION 

  

	 	1.1	In this Agreement, the following words shall have the following meanings, unless the context requires otherwise: 

 Affiliates shall have the meaning ascribed to it in the Consortium Agreement; 
 Agreement means this Co-ownership Agreement together with the attached Schedule; 
 Amending Party shall have the meaning ascribed to it in Clause 14.1; 
 Background IPR means any and all IPR in existence and already belonging to LSTM or CombinatoRx (as appropriate) prior to the Effective Date. For the avoidance of doubt, CombinatoRx’s Background IPR shall
include the Retained IPR; 
 Best Judgment means that degree of skill, diligence, prudence and foresight which as at the relevant time,
would reasonably and ordinarily be expected from a skilled experienced and reputable manufacturer and supplier of pharmaceuticals using the best techniques and practices for any given process, seeking in good faith to comply with its contractual
obligations, and complying with all applicable laws and Charitable Objectives; 
 Charitable Objectives shall have the meaning ascribed
to it in the Consortium Agreement; 
 Commercial Field means any commercial exploitation of the Foreground IPR in the Territory,
excluding the Filariasis Field; 
 Disease Endemic Countries shall have the meaning ascribed to it in the Consortium Agreement;

 Dispute Notice shall have the meaning ascribed to it in paragraph 3.1 of the Schedule; 
 Effective Date means 1 April 2008; 
 Employing Party shall have the meaning ascribed to it in Clause 5.5; 
 Expert shall have the meaning ascribed to it in
paragraph 3.3 of the Schedule; 
 Exploiting Party shall have the meaning ascribed to it in the Consortium Agreement; 
  

 Page 2 

 Filariasis Field means use of the Foreground IPR for the purposes of the Project, the Project
Research, the Charitable Objectives and/or the manufacture, supply and sale of the Products to the Disease Endemic Countries in the Territory and including the Parasitology Field; 
 Foreground IPR means any and all discoveries, inventions, improvements, materials, designs, works of ownership, databases and IPR conceived or
created by LSTM and/or CombinatoRx from the performance of the Project and/or the Project Research including the Patents and Product Candidates, but excluding the Background IPR and in the case of CombinatoRx, the Retained IPR; 
 IPR means any and all intellectual property rights including without limitation, copyright, software, moral rights, rights in data and database
rights and other protectable lists of information, rights in confidential information, trade secrets, inventions, patents, supplementary protection certificates, patent term extensions or equivalents, know-how, trade marks and design rights,
technical information, research and results whatsoever or howsoever arising anywhere in the Territory (whether registered or unregistered and including any applications for the protection or registration of these rights) throughout the full term
thereof and all renewals, reversions and extensions thereof whether now known or arising in the future in the Territory; 
 IP Steering
Committee means the committee made up of the representatives of LSTM and CombinatoRx and managed in accordance with the attached Schedule; 
 Parasitology Field means the use of the Foreground IPR for the treatment of diseases caused by filarial nematodes; 
 Patent(s) means any and all inventions created under the Foreground IPR which are the subject of a registered patent, patent application, supplementary protection certificate, patent term extension and/or equivalent, including any
and all future patents, patent applications, supplementary protection certificates, patent term extensions and/or equivalents arising in respect of such invention anywhere in the Territory; 
 Product Candidates means the screening results and Foreground IPR which have been identified as meeting the Target Product Profile and which have
been agreed in writing between the parties through the IP Steering Committee on or before June 30, 2010; 
 Products shall have
the meaning ascribed to it in the Consortium Agreement; 
 Project shall have the meaning ascribed to it in the Consortium Agreement;

  

 Page 3 

 Project Research shall have the meaning ascribed to it in the Consortium Agreement; 
 Relevant Claim shall have the meaning ascribed to it in Clause 12.4; 
 Relevant Jurisdiction means the jurisdictions of domicile of LSTM, CombinatoRx and any jurisdiction in which a Patent is registered; 
 Retained IPR means any IPR relating to CombinatoRx’s combination high throughput screening technology and any of CombinatoRx’s Background IPR relating to product candidates, materials, compounds and
combinations thereof; 
 Surrendering Party shall have the meaning ascribed to it in Clause 11; 
 Target Product Profile means the target product profile as agreed in writing between the parties through the IP Steering Committee for the purposes
of the Project, the Project Research, the Charitable Objectives and/or the manufacture, supply and sale of the Products in the Territory; 
 Territory means worldwide; 
 Transfer shall have the meaning ascribed to it in Clause 10.1; and 
 Transferring Party shall have the meaning ascribed to it in Clause 10.1. 
  

	 	1.2	This Agreement shall be binding on all its successors and assigns. 

  

	 	1.3	Any reference to any statute or statutory provision shall, unless the context otherwise requires, be construed as a reference to that statute or provision as from time to time
amended, consolidated, modified, extended, re-enacted or replaced. 

  

	 	1.4	The headings in this Agreement have been inserted for convenience only. They do not form part of this Agreement and do not affect its interpretation or construction.

  

	 	1.5	Unless the context requires otherwise, words denoting the singular shall include the plural and vice versa and words denoting any one gender shall include all genders and words
denoting persons shall include individuals, bodies corporate, unincorporated associations and partnerships. 

  

	 	1.6	Any lists or examples following the word including shall be interpreted without limitation to the generality of the preceding words. 

  

 Page 4 

	 	1.7	A Clause or Schedule is a reference to clause or schedule to this Agreement and the Schedules are to form part of the Agreement and shall be interpreted and construed as though they
were set out in this Agreement. 

  

	 	1.8	In the event of a conflict between: 

  

	 	1.8.1 	the terms of the main body of this Agreement and the terms of the Schedules, the terms of the main body of this Agreement shall prevail; or 

  

	 	1.8.2 	the terms of the Consortium Agreement and the terms of this Agreement, the terms of this Agreement shall prevail with regard to IPR only. 

  

	2	INTERESTS OF PARTIES 

 The parties shall own the
Foreground IPR as legal and beneficial joint tenants. For the avoidance of doubt, the parties hereby agree and acknowledge that this Agreement varies Section 36(1) and 36(3) of the Patents Act 1977 with respect to ownership of the Patents.

  

	3	FIELD OF USE 

  

	 	3.1	LSTM shall have the exclusive (even against CombinatoRx), perpetual, irrevocable, royalty free right to use the Foreground IPR in the Filariasis Field in the Territory without the
consent of CombinatoRx. For the avoidance of doubt, LSTM shall be entitled to grant to the Exploiting Party a license or sub-licence of the Foreground IPR within the Filariasis Field in the Territory without the consent of CombinatoRx.

  

	 	3.2	Subject to Clauses 3.3 and 3.4 below, CombinatoRx shall have the exclusive (even against LSTM), perpetual, irrevocable, royalty free right to use the Foreground IPR in the
Commercial Field in the Territory without the consent of LSTM. For the avoidance of doubt, CombinatoRx shall be entitled to grant licenses or sub-licenses of the Foreground IPR in the Commercial Field to third parties without the consent of LSTM.

  

	 	3.3	Subject to Clause 4.5, LSTM shall be entitled to grant to the Exploiting Party a license or sub-licence to use the Product Candidates within the Parasitology Field in the Territory
without the consent of CombinatoRx. 

  

 Page 5 

	 	3.4	LSTM shall be entitled to grant to the Exploiting Party a licence or sub-licence to use the Foreground IPR within the Commercial Field in the Territory with the prior written
consent of CombinatoRx (such consent not to be unreasonably withheld or delayed), provided that, such licenses or sub-licenses may not be granted by LSTM to the extent they are inconsistent with any licenses or sub-licences to use the Foreground IPR
within the Commercial Field which CombinatoRx had granted to a third party. 

  

	4	BACKGROUND IPR 

  

	 	4.1	LSTM and CombinatoRx hereby agree and acknowledge that each party shall retain the ownership of its own Background IPR. 

  

	 	4.2	Subject to Clause 4.4, LSTM and CombinatoRx hereby agree and acknowledge that the Retained IPR shall remain solely the property of CombinatoRx. 

  

	 	4.3	LSTM hereby grants to CombinatoRx a irrevocable, royalty-free, non-exclusive, non-assignable licence to use LSTM’s Background IPR for the purposes of the Project and the
Project Research. 

  

	 	4.4	CombinatoRx hereby grants to LSTM an non-exclusive, perpetual, irrevocable, royalty free, licence to use CombinatoRx’s Background IPR (including the Retained IPR) for the
purposes of the Project and the Project Research. 

  

	 	4.5	In the event that LSTM requires use of CombinatoRx’s Background IPR (including the Retained IPR) to the extent necessary in order for LSTM to use and exploit the Foreground IPR
within the Filariasis Field (including by way of a sub-licence to the Exploiting Party for use of the Foreground IPR within the Filariasis Field) or for LSTM to sub-licence such of CombinatoRx’s Background IPR to the Exploiting Party for the
purposes of using and exploiting the Product Candidates in the Parasitology Field and/or the Foreground IPR in the Commercial Field pursuant to Clause 3.4, the parties shall discuss in good faith and to the parties’ mutual satisfaction the
terms of such licence. 

  

	 	4.6	Each party will provide to each other and will subsequently maintain a complete list of any Background IPR (including the Retained IPR in the case of CombinatoRx) that is used in
the Project and/or the Project Research. 

  

 Page 6 

	 	4.7	CombinatoRx warrants and represents that, to the best of its knowledge, that any use of: 

  

	 	4.7.1	 CombinatoRx’s Background IPR by LSTM as set out above in Clause 4.4; and/or 

  

	 	4.7.2 	the Product Candidates by LSTM as set out above in Clauses 3.1 and 3.3; 

 will not infringe any third party Patents and subject to Clause 18 (Indemnity), CombinatoRx shall indemnify and keep indemnified, defend and hold harmless LSTM and its directors, officers, representatives, employees
and agents against all losses, costs and expenses (including any legal expenses and disbursements), claims, demands, suits or other actions arising from LSTM’s use, storage or disposal of CombinatoRx’s Background IPR in accordance with the
Research Project, except to the extent caused by the negligence or wilful misconduct of LSTM or the A-WOL Consortium. 
  

	5	PATENTS 

  

	 	5.1	Each of LSTM and CombinatoRx shall take appropriate steps to protect the Patents and/or the Foreground IPR, such steps may include without limitation, in relation to the Patents,
filing patent applications and taking all necessary precautions to maintain the confidentiality of any know-how. The process of filing, prosecuting, maintaining (including oppositions), preventing the infringement of and defending any of the Patents
and/or Foreground IPR shall be performed by CombinatoRx using its Best Judgment in accordance with the remainder of this Clause 5. Subject to Clause 5.3 below, CombinatoRx shall not charge LSTM any service fee for the provision of the services
relating to the filing, prosecution, maintaining, preventing the infringement of and/or defending any of the Patents and/or the Foreground IPR. 

  

	 	5.2	The filing, prosecuting and maintaining (including defending oppositions) of the Patents shall be determined by the IP Steering Committee. The defending and preventing infringement
of the Patents shall be determined in accordance with Clause 12. 

  

	 	5.3	All fees, costs, charges and expenses connected with filing, prosecuting and maintenance of (including oppositions) the Patents shall be borne and paid for by the parties in equal
shares, unless agreed otherwise in writing between the parties through the IP Steering Committee. An example of such circumstances may be if CombinatoRx wishes to register a Patent for use within the Commercial Field only, which would not be
applicable to the Filariasis Field, then in such circumstances, the parties may agree that CombinatoRx shall pay a larger proportion of the applicable fees, costs, charges and expenses. 

  

 Page 7 

	 	5.4	In the event that one of the parties is unable or unwilling to pay any amount due to be paid by it, the other party may pay the same and the amount so paid shall be a debt owed by
the defaulting party to the other party who makes payment. 

  

	 	5.5	Each of the parties (Employing Party) shall ensure that those of its employees and other staff working under its supervision or control who carry out work relating to the
Project and/or the Project Research shall assign all their right, title and interest in the same to the Employing Party and shall co-operate with the Employing Party to enable it to comply with its obligations under this Agreement. Each party and
its Affiliates shall undertake, at the reasonable request and expense of the other party, to sign or have signed any and all documents necessary in connection with the filing, prosecution, maintenance, extension, defence and enforcement of the
Patents and to take such other necessary actions as CombinatoRx, as the prosecuting party, may reasonably request in connection with the Patents. 

  

	 	5.6	The Employing Party shall be responsible for payment of any compensation that may be due to its staff under sections 40 to 43 of the Patents Act 1977, or under their contracts of
employment or otherwise, in respect of inventions made by such staff. 

  

	6	RENEWAL FEES 

  

	 	6.1	All renewal fees (including costs (if any) in connection with the payment of such fees necessary to keep the Patents (and any such other registered Foreground IPR, as appropriate))
in force shall be paid by the parties in equal shares, unless agreed otherwise in writing between the parties through the IP Steering Committee. An example of such circumstances may be if CombinatoRx wishes to renew the Patents or the relevant
Foreground IPR for use within the Commercial Field only, which would not be relevant to the Filariasis Field, then in such circumstances, the parties may agree that CombinatoRx shall pay a larger proportion of the renewal and/or maintenance fees.

  

	 	6.2	In default of payment of a renewal fee by CombinatoRx at least fourteen (14) days before the due date for payment the amount may be paid by LSTM and immediately after such
payment shall be recoverable as a contract debt from CombinatoRx and until so recovered shall be a charge upon CombinatoRx’s interest in the relevant Patents (and any such other registered Foreground IPR, as appropriate).

  

 Page 8 

	7	INDEPENDENT WORKING 

  

	 	7.1	CombinatoRx may use its interest in the Foreground IPR for its own profit within the Commercial Field without accounting to LSTM. All profits derived by CombinatoRx from, without
limitation, the sale, manufacture, letting or hire of any products manufactured by CombinatoRx in accordance with the Patents (or any one of them) or the license or sub-licence of Foreground IPR in the Commercial Field may be retained by CombinatoRx
for its own use and benefit. 

  

	 	7.2	LSTM may use its interest in the Foreground IPR within the Filariasis Field without accounting to CombinatoRx. Subject to Clause 9, all profits derived by LSTM from the sale and/or
licence of the Patents and/or the Foreground IPR, and/or the manufacture and/or sale of Products may be allocated by LSTM in accordance with the Consortium Agreement consistent with the Charitable Objectives. 

  

	8	LICENCE RESTRICTION 

 For the purposes of this
Agreement, the parties agree and acknowledge that Sections 8, 12 and 37 of the Patents Act 1977 shall be expressly excluded from this Agreement to the extent possible by law. 
  

	9	DIVISION OF PROFITS FROM LICENCE 

 All receipts
(whether by way of royalties or in any other manner whatsoever) derived from any licence under the Patents and/or the Foreground IPR granted jointly by the parties pursuant to Clause 3.4 shall be divided equally between the parties after payment of
any expenses concerned with the Patents and/or Foreground IPR including the cost of obtaining the licences. 
  

	10	SALE OR ASSIGNMENT OF INTEREST & RIGHTS OF PRE-EMPTION 

  

	 	10.1 	Subject to Clause 21.3, either party (the Transferring Party) may sell, assign, transfer, mortgage, charge or dispose of its interest in the Patents and/or the Foreground IPR
(Transfer) subject to the terms of this Agreement provided that the Transferring Party shall first give to the other party not less than six (6) months’ notice in writing of the Transferring Party’s intention to do so stating
the consideration and all the material terms of such proposed Transfer. 

  

 Page 9 

	 	10.2 	If within such six (6) month period the other party shall give notice to the Transferring Party of the other party’s desire to purchase or acquire such interest in the
Patents and/or Foreground IPR on the same terms (unless agreed otherwise in writing between the parties), the Transferring Party shall Transfer the Patents and/or the Foreground IPR to the other party accordingly. The Transferring Party will
undertake such steps and execute such documents as are necessary in order to effect such Transfer of the Patents and/or the Foreground IPR to the other party. 

  

	 	10.3 	If the other party does not exercise its rights under Clause 10.2 above and consents to the Transfer to a third party in accordance with Clause 10.1 above, then the Transferring
Party shall use all reasonable endeavours to procure the novation to the third party of all the rights and obligations under this Agreement in relation to the Transferring Party’s interests in the relevant and applicable Patents and/or
Foreground IPR which are the subject of the Transfer. 

  

	 	10.4 	For the avoidance of doubt, the provisions of Clause 10 and Clause 11 shall not apply to licences granted by the parties to third parties pursuant to Clause 3.

  

	11	SURRENDER 

 If either party wishes to surrender the
Patents and/or the Foreground IPR (or any of them) that party (the Surrendering Party) shall give to the other party not less than six (6) months’ prior written notice of the Surrendering Party’s wish to do so. If the other
party wishes to maintain the Patents and/or Foreground IPR (or any of them) it shall inform the Surrendering Party of such intention within the six (6) month period and the Surrendering Party shall assign its share, including all the
Surrendering Party’s right and title to and interest in the Patents and/or the Foreground IPR together with all rights of action, powers and benefit to the same belonging or accrued by way of gift, to the other party. The other party shall
accept such assignment and indemnify the Surrendering Party in respect of any liability arising out of such surrender but not in respect of any act arising before the date of surrender. 
  

 Page 10 

	12	INFRINGEMENT PROCEEDINGS 

  

	 	12.1 	Subject to Clause 12.3, if the parties agree to defend or prevent any infringement in respect of the Patents and/or the Foreground IPR (as appropriate), all costs, charges and
expenses of or incidental to or consequent upon such proceedings shall be borne and paid by the parties in equal shares, unless agreed otherwise in writing between the parties through the IP Steering Committee. An example of such circumstances may
be if CombinatoRx wishes to defend or prevent the infringement in respect of the Patents and/or the Foreground IPR in the Commercial Field only, which would not be applicable to the Filariasis Field, then in such circumstances, the parties may agree
that CombinatoRx shall bear more of the costs and expenses relating to such defence and/or prevention of infringement. 

  

	 	12.2 	All damages or other sums recovered in such proceedings and any other benefit of the judgment or order of such proceedings shall be for the benefit of LSTM in respect of the
Filariasis Field and for the benefit of CombinatoRx in respect of the Commercial Field. 

  

	 	12.3 	If one of the parties shall be unwilling to take such proceedings or to defend proceedings for the revocation of the Patents and/or the Foreground IPR (or any of them) it shall
grant to the other party the right to do so allowing such other to use its name as co-claimant and the other party may at its own expense in all respects take such proceedings or defence and shall be solely entitled to all damages or other sums
recovered and to the full benefit of any judgment but shall indemnify and keep indemnified the party unwilling to take such proceedings for any damages or costs or any other penalty as may be awarded against the co-claimants either jointly or
severally. 

  

	 	12.4 	If any third party makes a claim, or notifies an intention to make a claim, against either party relating to the Foreground IPR and/or the Patents (Relevant Claim), the party
which is the subject of the Relevant Claim shall: 

  

	 	12.4.1 	as soon as reasonably practicable, give written notice of the Relevant Claim to the other party specifying the nature of the Relevant Claim in detail; 

  

	 	12.4.2 	not make any admission of liability, agreement or compromise in relation to the Relevant Claim without the prior written consent of the other party (such consent not to be
unreasonably withheld or delayed); and 

  

 Page 11 

	 	12.4.3 	after consultation with the other party, take such action as is reasonably required to avoid, dispute, compromise or defend the Relevant Claim. 

  

	13	MARKING OF PRODUCTS 

 All products made in
accordance with the Patents shall be marked in a legible manner in some conspicuous place before sale or offer for sale by or on behalf of either party with the words ‘Patent No’ together with the numbers of the relevant Patents, or if it
is not practicable to mark such products, the packages or wrappings associated with them shall be so marked. 
  

	14	AMENDMENT OF SPECIFICATION 

  

	 	14.1 	Subject to Clause 5, no application or motion to amend the specification or claims of the Patents shall be made by either party (Amending Party) without giving reasonable
prior written notice to the other party of its intention to do so. 

  

	 	14.2 	If the other party thinks that such an application or motion may have a material adverse effect on the remaining Patents (or any of them), then the other party shall notify the
Amending Party in writing providing its reasonable opinion and details of the suspected material adverse effect on the remaining Patents (or any of them). 

  

	 	14.3 	In the event that notice is given under Clause 14.2, the IP Steering Committee shall determine whether or not such an application or motion to amend the Patents (or any of them)
should proceed. 

  

	15	ACKNOWLEDGEMENT 

 The certificate of grant of the
Patents shall be retained by CombinatoRx who hereby acknowledges the right of LSTM to production and delivery of copies of the certificates and undertakes to keep them in safe custody. CombinatoRx shall hold the certificate of grant of the Patents
specifically registered in the Filariasis Field on trust for LSTM and shall deliver up such certificates immediately on request by LSTM. 
  

	16	REGISTRATION 

 This Agreement shall be registered by
LSTM as patentee at the Patent Office of the United Kingdom in respect of the Patents and CombinatoRx shall register this Agreement with such other authorities in the Territory as are necessary for and on behalf of LSTM. 
  

 Page 12 

	17	IP STEERING COMMITTEE 

 The parties shall each
nominate a representative for the IP Steering Committee and the IP Steering Committee shall act in accordance with the Schedule to this Agreement. 
  

	18	INDEMNITY 

 The parties hereby agree and acknowledge
that the indemnity given by CombinatoRx pursuant to Clause 4.7 of this Agreement, Clause 3.11 of the Consortium Agreement and Clause 5.10 of the Project Agreement shall be capped to the sums payable by LSTM to CombinatoRx pursuant to
CombinatoRx’s involvement under the Consortium Agreement and the Project Agreement (as defined under the Consortium Agreement). 
  

	19	CONFIDENTIALITY 

 Except as provided in Clause 16
with respect to the registration of this Agreement, LSTM and CombinatoRx shall keep confidential the terms and conditions and existence of this Agreement, provided that, LSTM shall be entitled to disclose this Agreement and its contents to the A-WOL
Consortium members and The Foundation (as defined in the Consortium Agreement) and CombinatoRx may disclose this Agreement as required by applicable law provided that CombinatoRx notifies LSTM prior to any such disclosure. 
  

	20	TERM AND TERMINATION 

 This Agreement shall commence
on the Effective Date and shall continue in full force and effect until the expiry of all IPR in the Foreground IPR. 
  

	21	GENERAL 

  

	 	21.1 	This Agreement (together with the Consortium Agreement and the Project Agreement between the parties) supersedes any prior written or oral agreements, arrangements and undertakings
between the parties relating to the subject matter of this Agreement and shall, together with the attached Schedule constitute the entire agreement and understanding between the parties relating to its subject matter. The parties shall act
reasonably in implementing any additions or modifications which may be required by The Foundation. The parties hereby agree and acknowledge that the Interim Consortium Agreement dated 25 April 2007 between LSTM and CombinatoRx shall be deemed
to expire on 31 March 2008. 

  

 Page 13 

	 	21.2 	The parties acknowledge and agree that, in entering this Agreement, they are not relying upon any representation, warranty, promise or assurance made or given by the other parties
or any other person, whether or not in writing, at any time prior to the Effective Date which is not expressly set out in this Agreement. 

  

	 	21.3 	Except as set out in this Agreement, no rights or obligations of any party arising from or under this Agreement (including the exercise and enforcement thereof) may be assigned or
transferred or otherwise delegated in whole or in part to any third party without the prior written approval of the other party; provided that, CombinatoRx, without the consent of LSTM, may assign this Agreement and its rights and obligations
hereunder to: 

  

	 	21.3.1 	any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates; or

  

	 	21.3.2 	any direct or indirect affiliate of CombinatoRx. 

 In the
event that a party assigns or transfers, or otherwise delegates to a third party as aforesaid the transferring party shall remain fully responsible and liable for the acts and omissions of any such third party. In the event that this Agreement is
transferred to a third party (including without limitation, under sub-clauses 21.3.1 or 21.3.2 above), the transferring party shall use all reasonable endeavours to procure a novation from the third party of all of the transferring party’s
rights and obligations under this Agreement. 
  

	 	21.4 	Nothing in this Agreement shall constitute, be deemed to constitute or imply a partnership, agency, employment or other relationship between the parties other than the contractual
relationship expressly provided for in this Agreement and none of the parties shall hold itself out or act in such a way as may give that impression (including by using another party’s name) or do anything to bind or create any obligation or
responsibility upon another party without that other party’s prior written approval. 

  

	 	21.5 	No delay or failure by a party to exercise or enforce any right, power or remedy under this Agreement shall constitute or operate as a waiver of that right, power or remedy or any
other right, power or remedy under this Agreement or operate so as to prevent the subsequent exercise or enforcement of any such right, power or remedy. Any waiver must be made by the waiving party in writing to be effective.

  

 Page 14 

	 	21.6 	Any notice, consent, approval, agreement or other document required under this Agreement shall, in the absence of any express provision to the contrary shall be in writing in the
English language and shall be deemed to have been duly given if left at or sent by hand or by registered post or recognised international overnight courier by fax to a party at the address set out at the beginning of this Agreement for such party or
such other address as one party may from time to time designate by written notice to the other and will be deemed to have been received by the other party; (i) two (2) Working Days following the date of dispatch if the notice or other
document is sent by registered post or recognised international overnight courier, or (ii) seven (7) Working Days following the date of dispatch if the notice or other document is sent by registered airmail post, or
(iii) simultaneously with the delivery if sent by hand, or (iv) simultaneously with transmission if sent by fax provided that the sending transmitting party keeps a copy of a transmission report illustrating successful transmission to the
appropriate fax number. 

  

	 	21.7 	Any variation or amendment of this Agreement shall be made in writing and signed by a duly authorised representative of each of the parties. 

  

	 	21.8 	If any provision of this Agreement is held by any court or other competent authority to be void or unenforceable (in whole or part), the other provisions of this Agreement and the
remainder of the affected provisions shall continue to be valid. 

  

	 	21.9 	The rights and remedies provided in this Agreement are cumulative and not exclusive of any rights or remedies otherwise provided by law. 

  

	 	21.10 	This Agreement shall be executed as a deed and shall be governed by and construed in accordance with English law. The parties irrevocably agree that the courts of England have
exclusive jurisdiction to decide and to settle any dispute or claim arising out of or in connection with this Agreement. The parties hereby agree and acknowledge that the terms of this Agreement shall prevail to the extent possible by law over any
law in any Relevant Jurisdiction. 

  

	 	21.11 	This Agreement may be executed in one (1) or more counterparts by the parties, each of which, when so executed shall be deemed to be an original and all of which taken together
shall constitute one and the same instrument, provided that this Agreement shall be of no force and effect until the counterparts are exchanged. Signatures may be exchanged by facsimile or electronic means with original signatures to follow by post.
Each of the parties agrees to be bound by its own facsimile or electronic form signature and that is accepts the facsimile or electronic form signature of the other party. 

  

 Page 15 

 SCHEDULE 
 IP STEERING COMMITTEE 
  

	1	General Performance Obligations 

  

	 	1.1	Each party will, within fourteen (14) days of signature of this Agreement, nominate one (1) representative for the IP Steering Committee. Each party shall have the right
to replace its respective IP Steering Committee representatives upon written notice to the other party. Each party shall be entitled to bring in respect of an agenda item at a meeting of the IP Steering Committee such minimum numbers of non-voting
advisors, consultants and such other attendees which such party considers in good faith necessary or useful to such party, provided that, prior notice of such attendees has been given to the other party in advance of the relevant IP Steering
Committee meeting. 

  

	 	1.2	The IP Steering Committee will be chaired by the Senior Executive Officer, being Professor Mark Taylor of LSTM or his nominee. The chairman shall not have a casting vote.

  

	 	1.3	The responsibilities of the IP Steering Committee shall include: 

  

	 	1.3.1 	determining the Target Product Profiles and the Product Candidates; 

  

	 	1.3.2 	determining in which jurisdictions the Patents should be filed; 

  

	 	1.3.3 	scope of claims of the Patents or amending the specification of the Patents; 

  

	 	1.3.4	 determining the strategy and course of action with respect to: 

  

	 	1.3.4.1 	the filing, prosecution and/or maintenance of all such actions regarding the Patents and/or the Foreground IPR, including any patent granting authority; 

  

	 	1.3.4.2 	the enforcement (including defending any oppositions) of any Patents and/or Foreground IPR; 

  

	 	1.3.4.3 	the defence of any Patents and/or Foreground IPR; and 

  

	 	1.3.5	  in these matters, the IP Steering Committee shall seek to operate by consensus, provided that, for matters relating to the Patents in the Commercial Field, CombinatoRx shall
have the power of veto and for matters relating to the Patents in the Filariasis Field, LSTM shall have the power of veto. 

  

 Page 16 

	 	1.4	The IP Steering Committee may participate in meetings by phone-conference, video-conference or any other technology that enables participation in the meeting with communication
which is interactive and simultaneous. 

  

	 	1.5	The quorum for a meeting of the IP Steering Committee will be one (1) representative of each party, or his/her alternative, in addition to the Chairman (as per paragraph 1.2
above) present in person or by phone-conference, video-conference or other technology mentioned above. 

  

	 	1.6	The parties will ensure that the IP Steering Committee meets at least bi-annually by means set out in paragraph 1.4 above or at venues to be agreed, and in default of agreement at
LSTM, and at any other time as reasonably requested by either of the parties. 

  

	 	1.7	Meetings of the IP Steering Committee will be convened with at least seven (7) days’ written notice in advance, including an agenda. Minutes of the meetings of the IP
Steering Committee will be prepared by the Chairman and sent to each party within fourteen (14) days after each meeting for review and approval. Each party shall sign the agreed version of the meeting minutes and the Chairman shall keep a copy
of the signed meeting minutes. 

  

	 	1.8	At six (6) monthly intervals and/or such times as the Senior Executive Office reasonably requests, the parties will provide to the IP Steering Committee a report summarising
any developments and details of the Foreground IPR in order to assess whether or not a Patent application can be made. 

  

	 	1.9	Each party shall bear its own expenses of its IP Steering Committee members and/or attendees, including attendance at any IP Steering Committee meetings. 

 

	2	IP Steering Committee Terms of Office 

 An IP
Steering Committee member’s term of office automatically terminate if he/she is: 
  

	 	2.1	incapable whether mentally or physically of managing his or her own affairs; 

  

	 	2.2	is absent from more than two (2) consecutive IP Steering Committee Meetings; 

  

	 	2.3	is removed from the IP Steering Committee by the written agreement of the parties; or 

  

	 	2.4	resigns by written notice to the IP Steering Committee. 

  

 Page 17 

	3	Dispute Resolution Procedure 

  

	 	3.1	In the event of any dispute between the parties arising in connection with this Agreement, the parties shall use their best endeavours to promptly and amicably resolve such dispute
by consensus in good faith through the IP Steering Committee. If the parties are unable to resolve such dispute, then any party may forthwith give notice (“Dispute Notice”) to the other party that it wishes such dispute to be
referred to a designated senior officer of each of the parties. 

  

	 	3.2	In any event of a Dispute Notice being served, each of the parties shall within fourteen (14) days of the service of such Dispute Notice prepare and circulate to the designated
senior officer of each of the parties a memorandum or other form of statement setting out its position on the matter in dispute and its reasons for adopting that position. Each memorandum or statement shall be considered by the designated senior
officers of each of the parties who shall endeavour to resolve the dispute. If designated senior officers of each of the parties agree upon a resolution or disposition of the matter, they shall each sign a statement which sets out the terms of their
agreement. 

  

	 	3.3	In the event the designated senior officers of each of the parties are unable to resolve a dispute within sixty (60) days of its being referred to them, the parties shall refer
the matter to an independent expert with knowledge in pharmaceutical product development jointly selected by the designated senior officers of each of the parties (the Expert). 

  

	 	3.4	In the event the designated senior officers of each of the parties cannot agree upon the designation of the Expert, the parties shall request the International Chamber of Commerce
(ICC) to select the Expert. In each case, the Expert shall be selected having regard to his/her suitability to determine the particular dispute or difference on which the Expert is being requested to determine. 

  

	 	3.5	Unless otherwise agreed between the designated senior officers of each of the parties, the following rules shall apply to the appointment of the Expert. The fees of the ICC and the
Expert shall be shared equally by the parties. The Expert shall be entitled to inspect and examine all documentation and any other material which the Expert may consider to be relevant to the dispute. The Expert shall afford each party a reasonable
opportunity (in writing or orally) of stating reasons in support of such contentions as each party may wish to make relative to the matters under consideration. The Expert shall give notice in writing of his determination to the parties within such
timescale as stipulated in his terms of appointment or in the absence of such stipulation as soon as practicable but in any event within four (4) weeks from the reference of the dispute or difference to him/her. 

  

 Page 18 

	 	3.6	Any determination by the Expert of a dispute or difference shall not be binding on the parties and the parties shall be entitled to pursue their legal rights in accordance with
Section 12.11 of the Consortium Agreement. 

  

 Page 19 

 IN WITNESS WHEREOF duly authorised representatives of the parties have signed this Deed on the date first written
above 
  

			
	 Executed as a DEED for and on behalf of
	  	 )

		
	 LIVERPOOL SCHOOL OF TROPICAL MEDICINE
	  	 )

		
	 Signature /s/ S. A.
Ward                        
	  	 Signature /s/ R. E.
Holland                        

	 Name S. A. Ward
	  	 Name R. E. Holland

	 Title: Director
	  	 Title: Company Secretary

	 Date 10/3/2008
	  	 Date 10/6/2008

		
	 Executed as a DEED for and on behalf of
	  	 )

		
	 COMBINATORX, INCORPORATED
	  	 )

		
	 Signature /s/ Alexis
Borisy                        
	  	 Signature /s/ Jason F.
Cole                        

	 Name Alexis Borisy
	  	 Name Jason F. Cole

	 Title: President and Chief Executive Officer
	  	 Title: Secretary

	 Date 10/8/2008
	  	 Date 10/8/2008

		
	 Executed as a DEED for and on behalf of
	  	 )

		
	 COMBINATORX (SINGAPORE) PTE. LTD
	  	 )

		
	 Signature /s/ Ralf Altmeyer
                        
	  	 Signature /s/ Esther
Au                        

	 Name Ralf Altmeyer
	  	 Name Esther Au

	 Title: President and Director
	  	 Title: Company Secretary

	 Date 10/8/2008
	  	 Date 10/8/2008

  

 Page 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]